Cascadian Therapeutics, Inc. (NASDAQ:CASC) has received a consensus rating of “Hold” from the seven analysts that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $6.00.

A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald reaffirmed a “hold” rating and set a $4.00 price target on shares of Cascadian Therapeutics in a research note on Monday. ValuEngine downgraded shares of Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Zacks Investment Research downgraded shares of Cascadian Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Cowen and Company reaffirmed a “buy” rating on shares of Cascadian Therapeutics in a research note on Wednesday, August 9th. Finally, Barclays PLC assumed coverage on shares of Cascadian Therapeutics in a research note on Wednesday, September 6th. They set an “underweight” rating and a $4.00 price target on the stock.

Hedge funds have recently bought and sold shares of the business. Segantii Capital Management Ltd bought a new position in Cascadian Therapeutics during the first quarter valued at $243,000. Baupost Group LLC MA increased its position in Cascadian Therapeutics by 109.3% during the first quarter. Baupost Group LLC MA now owns 8,721,079 shares of the biopharmaceutical company’s stock valued at $36,105,000 after acquiring an additional 4,554,413 shares during the last quarter. Citadel Advisors LLC bought a new position in Cascadian Therapeutics during the first quarter valued at $142,000. Sabby Management LLC bought a new position in Cascadian Therapeutics during the first quarter valued at $669,000. Finally, Redmile Group LLC bought a new position in Cascadian Therapeutics during the first quarter valued at $16,860,000. Institutional investors and hedge funds own 82.55% of the company’s stock.

Shares of Cascadian Therapeutics (NASDAQ CASC) opened at 3.53 on Wednesday. The company’s market cap is $178.45 million. The firm has a 50-day moving average of $3.76 and a 200-day moving average of $3.94. Cascadian Therapeutics has a one year low of $3.18 and a one year high of $10.98.

Cascadian Therapeutics (NASDAQ:CASC) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.06. During the same quarter in the previous year, the company posted ($1.57) EPS. Equities research analysts forecast that Cascadian Therapeutics will post $5.02 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/cascadian-therapeutics-inc-casc-given-consensus-recommendation-of-hold-by-analysts/1557866.html.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Analyst Recommendations for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.